Follow
Samantha Nyovanie
Samantha Nyovanie
New York University, NYU Langone
Verified email at nyulangone.org
Title
Cited by
Cited by
Year
Cellular and humoral immunity to SARS‐CoV‐2 infection in multiple sclerosis patients on ocrelizumab and other disease‐modifying therapies: a multi‐ethnic observational study
I Kister, Y Patskovsky, R Curtin, J Pei, K Perdomo, Z Rimler, I Voloshyna, ...
Annals of Neurology 91 (6), 782-795, 2022
222022
Hybrid and vaccine‐induced immunity against SAR‐CoV‐2 in MS patients on different disease‐modifying therapies
I Kister, R Curtin, J Pei, K Perdomo, TE Bacon, I Voloshyna, J Kim, ...
Annals of Clinical and Translational Neurology 9 (10), 1643-1659, 2022
112022
Molecular mechanism of phosphopeptide neoantigen immunogenicity
Y Patskovsky, A Natarajan, L Patskovska, S Nyovanie, B Joshi, B Morin, ...
Nature communications 14 (1), 3763, 2023
92023
Longitudinal study of humoral and cellular responses to COVID-19 mRNA vaccines with and without 3rd (" booster") dose in MS patients on ocrelizumab: 24-week results from VIOLA …
I Kister, A Piquet, R Curtin, A Yu, I Voloshyna, V Yogambigai, S Nyovanie, ...
MULTIPLE SCLEROSIS JOURNAL 28 (3_ SUPPL), 842-843, 2022
12022
Antibody and T-cell responses to SARS-CoV-2 vaccines in MS patients on Ocrelizumab and other disease-modifying therapies: preliminary results of an ongoing, prospective study
I Kister, Y Patskovsky, I Voloshyna, N Ferstler, R Curtin, V Yogambigai, ...
MULTIPLE SCLEROSIS JOURNAL 27 (2_ SUPPL), 755-756, 2021
12021
Longitudinal study of immunity to SARS‐CoV2 in ocrelizumab‐treated MS patients up to 2 years after COVID‐19 vaccination
I Kister, R Curtin, AL Piquet, T Borko, J Pei, BL Banbury, TE Bacon, A Kim, ...
Annals of Clinical and Translational Neurology, 2024
2024
Structure of native four-repeat satellite III sequence with non-canonical base interactions
E Chen, M Trajkovski, HK Lee, S Nyovanie, KN Martin, WL Dean, ...
Nucleic Acids Research 52 (6), 3390-3405, 2024
2024
Hybrid and vaccine-induced immunity against SAR-CoV-2 in MS patients on different disease-modifying therapies (vol 10, pg1643, 2022)
I Kister, R Curtin, J Pei, K Perdomo, TE Bacon, I Voloshyna, J Kim, ...
ANNALS OF CLINICAL AND TRANSLATIONAL NEUROLOGY, 2023
2023
Humoral and Cellular Responses to SARS-CoV-2 Vaccines in MS Patients on Ocrelizumab and Other Disease-Modifying Therapies: A Prospective Study From NYU Multiple Sclerosis Care …
I Kister, Y Patskovsky, R Curtin, I Voloshyna, K Perdomo, Z Rimler, J Pei, ...
Neurology 98 (18_supplement), 2697, 2022
2022
Vaccine against SARS-CoV2-generated Immunity in Ocrelizumab-treated Patients: Longitudinal Assessments (VIOLA): study design and early results
I Kister, A Piquet, Y Patskovsky, I Voloshyna, N Ferstler, R Curtin, ...
MULTIPLE SCLEROSIS JOURNAL 27 (2_ SUPPL), 795-796, 2021
2021
Engineering T cells with improved TCR-CD3 interaction for optimal tumor killing
V Yogambigai, A Natarajan, C Ge, Z Yuan, K Li, J Kim, HW Shin, ...
The Journal of Immunology 206 (1_Supplement), 25.02-25.02, 2021
2021
Biophysical studies of G-quadruplex DNA in complexes with small molecule ligands
A Yett, S Nyovanie, L Yatsunyk
ABSTRACTS OF PAPERS OF THE AMERICAN CHEMICAL SOCIETY 256, 2018
2018
Synthesis of Organosiloxanes and Organoclays for Polymer-clay Nanocomposites
ST Nyovanie
Amherst College, 2017
2017
The system can't perform the operation now. Try again later.
Articles 1–13